Press "Enter" to skip to content

Pre-clinical findings indicate UV-A light device eradicates viruses and bacteria

In a prospectus supplement dated June 4, 2021, filed with the US Securities and Exchange Commission, Aytu BioPharma, Inc. (NASDAQ: AYTU), disclosed that the Company’s…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $89 for first member and $25 for each additional member.